ISCR has a trailing P/E of 3 on revenues of $18,000,000. They are on the verge of possible patent acceptance for their electronic medical records platform. The following recent news is also a strong positive indicator that ISCR could become a very lucrative company.
==========================================
InstaCare Subsidiary Inks 5-Year Exclusive Pact for Distribution of Proprietary Diabetes Test Strip Into $9.8 Billion Testing Market
-- AGREEMENT GRANTS EXCLUSIVE RIGHTS TO A PROPRIETARY DIAGNOSTIC PRODUCT DESIGNED TO WORK ON EXISTING FDA APPROVED PLATFORMS IN USE WORLDWIDE
-- CONTRIBUTING PROFIT MARGINS ARE ANTICIPATED TO BE 400% HIGHER VS. CURRENT PRODUCT LINES
-- VALUE PROPOSITION INCLUDES EXPECTED 50% COST ADVANTAGE VS. CURRENT PLATFORM DIAGNOSTICS
-- COMPANY PROJECTS SIGNIFICANT 3Q 2010 REVENUES AND ANTICIPATES CAPTURE OF 5% MARKET SHARE OF EXPECTED $12 BILLION MARKET BY 2012
==========================================
Business Summary
instaCare Corp., through its subsidiaries, distributes prescription and non-prescription diagnostics and drugs, and home testing products in the United States. It offers bulk prescription drugs on a wholesale basis to clients; diabetes diagnostics and supplies, including diabetic testing strips and associated diagnostic products; and various lines of ostomy, wound care, and post-surgery medical products to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company also offers MD@Hand and MD@Work cell phone-based medical communication network products to the medical insurance and pharmacy benefits management segments of the healthcare markets. These cell phone-based medical communication network products provide physicians with information at the point of care. The company was founded in 2000 and is based in Westlake Village, California.
Shares Outstanding.....86.9M
Float..................51.4M
Annual Revenues TTM....$18.7M
Debt...................$1.4M
Currently trading at .08 |
